though not emphasized, in five of the subjects in whom cardiac output measurements were obtained, the cardiac index (CI) increased an average of 1.4 Uimin.2 When slightly lower doses (1.3 to 3.6 pug/kg/min) were administered to an additional six patients with congestive heart failure, increases in cardiac output, GFR, or renal plasma flow were small and statistically insignificant; only sodium excretion was significantly increased.2 Despite the observed increase in cardiac output and the fact that renal function improved only in normal volunteers, stability of arterial pressure led to the suggestion that dopamine produces selective renal vasodilatation. This review evaluates the available data regarding whether dopamine is indeed a selective vasodilator in surgical patients and focuses on two critical issues: whether dopamnine enhances renal function and whether it provides any protection from developing renal failure.
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ANIMAL STUDIES
Numerous human and animal studies demonstrate increased renal blood flow and decreased renal vascular resistance after dopamine administration.37 However, these studies either demonstrate a concurrent increase in cardiac output4'6 or do not report cardiac output data. 3'5'7 Studies that look at the effects of dopamine on renal vessels and renal blood flow, independent of cardiac effects, have produced mixed results. In a rat, split-kidney, hydronephrotic model that allowed direct observation of renal vessels, an increase in the diameter of renal arcuate, interlobar, and afferent and efferent arterioles was seen with direct application of low concentrations of dopamine (1 to 30 11M).8 At higher concentrations (>100 ,tM), dopamine decreased renal vessel diameter. This vasoconstrictive effect was blocked by phentolamine, suggesting a direct alpha-adrenergic effect of dopamine at higher concentrations. Another study noted decreases in renal vascular resistance (19%) and increases in renal blood flow (17%) during infusion of fenoldopam (a specific dopamine DA-1 receptor agonist).S Despite this increase in renal blood flow, there was no increase in GFR or single nephron GFR. More importantly, urinary flow rate, sodium excretion, and potassium excretion increased with DA-1 stimulation, independent of any effect on GFR, reflecting a diuretic effect of the dopamine agonist. Dopamine is known to have direct effects on renal function independent of its hemodynamic effects. In renal tubular cells, dopamine inhibits Na/K ATPase, causing decreased sodium reabsorption and impaired tubuloglomerular feedback.5'9"0 The diuresis and natriuresis seen after dopamine administration are more likely caused by this direct effect of dopamine rather than to hemodynamic alteration.
STUDIES IN SURGICAL PATIENTS
A number of studies examining the use of low-dose dopamine in the perioperative period have been published in the last 10 years. 11-16 Most involve relatively small numbers of patients and lack the statistical power to detect any benefit in preventing renal failure, fortunately a relatively rare complication. A prospective, randomized, double-blind study of 48 liver transplant patients examined the effect of low-dose dopamine (3 ,ug/kg/min for 48 hours) on the incidence of renal insufficiency; the treatment group failed to show any benefit in postoperative urine output, GFR, or the need for dialysis. " Similarly, dopamine had no effect on liver function, portal venous flow, or hepatic artery flow; the only measured parameter that dopamine significantly increased was heart rate. In another prospective, randomized, double-blind, placebo-controlled study of 37 aortic surgery patients receiving 3 ,ug/kg/min of dopamine for 24 hours, an insignificant increase in urine output was detected (9 cc/hr), but there was no effect on creatinine clearance or the incidence of renal failure.'2 Of note, three of the four patients who had perioperative myocardial infarction were in the treatment arm. A third prospective, randomized, nonblinded study of low-dose dopamine in 23 patients undergoing surgical relief of obstructive jaundice showed no significant improvement in creatinine clearance, urine output, or the incidence of renal failure. '3 In patients with cardiac surgery, the data supporting lowdose dopamine as a selective renal protective agent are similarly inconclusive. In one study performed in postoperative coronary bypass patients, significant increases in urinary output, creatinine clearance, and sodium excretion were seen with dopamine infusions of 200 jug/min.'4 The cardiac index also was significantly increased, although heart rate was unaffected. However, in another study of coronary artery bypass patients, the same dose of dopamine increased CI but did not change urine output, creatinine clearance, free water clearance, or the incidence of renal insufficiency.'5 When dopamine and dobutamine were titrated to the same CI in postoperative cardiac surgical patients, both agents increased renal plasma flow and glomerular filtration; however, diuresis, natriuresis, and kaliuresis were greater with dopamine.'6 Although some animal and human studies4'6 have suggested that dopamine may additionally increase renal blood flow by a direct effect on renal arterioles, the functional significance of this mechanism is unclear because indices of renal function (GFR, creatinine clearance) were not measured in those studies. Direct renal vasodilatory action could actually be detrimental to glomerular filtration if both efferent and afferent arterioles are affected, via a reduction in glomerular capillary hydrostatic pressure. Taken together, these studies suggest that although dopamine may have a diuretic effect, it appears to increase renal function (creatinine clearance, GFR) only when cardiac output in increased.
STUDIES IN CONGESTIVE HEART FAILURE AND CRITICAL ILLNESS
Because low-dose dopamine is both an inotrope and a diuretic, one might expect salutary effects in patients with congestive heart failure; however, available data do not support this contention. When administered to elderly patients with congestive heart failure, low-dose dopamine did not increase GFR, effective renal plasma flow, or urine output. '7 Similarly, in patients with cardiomyopathic heart failure, dopamine (4 Ag/kg/min) increased CI, but the number of premature ventricular contractions also increased. '8 In this study, no improvement in creatinine clearance, renal blood flow, or urine output was observed. In a diverse population of critically ill patients, dopamine (200 ,tg/min) increased heart rate and urine volume but not creatinine clearance.'9 Dobutamine (175 ,ug/kg/min), on the other hand, significantly increased heart rate, mean arterial pressure, CI, and creatinine clearance but had no effect on urine output. Low-dose dopamine appears to have weak diuretic effects in critically ill patients and serves as a poor substitute for more effective inotropic regimens when renal function is compromised.
The concomitant use of low-dose dopamine and norepinephrine is clinically popular because of the belief that dopamine can ameliorate norepinephrine-induced mesenteric and renal vasoconstriction. However, in critical illness, no studies have shown any beneficial effect of dopamine other than diuresis. Nonseptic animal studies and studies in human volunteers suggest that low-dose dopamine does reverse norepinephrine-induced renal vasoconstriction and increase renal blood flow.4'20 The effects of norepinephrine and dopamine in sepsis and critical illness may be different Vol. 227 * No. 4 than in the normal state, however. In septic shock patients, by improving mean arterial pressure, norepinephrine may actually increase rather than decrease renal blood flow.21 '22 Furthermore, the renal hemodynamic effects of low-dose dopamine in septic shock are completely unknown. In a dog endotoxin shock model treated with norepinephrine, lowdose dopamine failed to increase renal blood flow or improve renal function. 23 Similarly, in a recent prospective trial of norepinephrine or epinephrine infusion to support blood pressure in patients with septic shock, the addition of low-dose dopamine (2 ,ug/kg/min) failed to improve either creatinine clearance or urine output.24 The 
DETRIMENTAL EFFECTS
Because it is a naturally occurring neurotransmitter, exogenous dopamine administration may influence many neurohumoral pathways. For example, even after brief administration of dopamine (<24 hours), levels of prolactin, thyroid-stimulating hormone, T3, T4, and growth hormone are significantly decreased.28-30 T-cell proliferation is also significantly inhibited by dopamine infusion.29 The significance of these effects on hormones and immune function is unknown.
In an endotoxin pig model, dopamine had no beneficial effect on splanchnic or renal blood flow compared to norepinephrine or placebo.3' Furthermore, dopamine may have deleterious effects on splanchnic blood flow. Splanchnic ischemia during hemorrhage, when assessed by mesenteric oxygen extraction, appeared to worsen when pigs received 2 ,ug/kg/min of dopamine.32 In a study of septic humans, high-dose dopamine administration appeared to decrease splanchnic perfusion (measured by gastric tonometry) despite increasing CI and total oxygen delivery. 33 Dopamine also has substantial effects on cardiopulmonary hemodynamics. In several studies, low-dose dopamine increased pulmonary artery wedge pressure while decreasing pulmonary vascular resistance. In essence, "renal dose" dopamine is two drugs in one: a mild sympathomimetic providing weak inotropic and chronotropic support, and a potent diuretic with direct natriuretic effects on the nephron. Although laboratory data suggest that dopamine may increase renal blood flow directly through dilation of the renal vasculature, the clinical significance of this remains uncertain. Clinical studies seem to indicate that dopamine improves renal function only when cardiac performance is concurrently enhanced, and it may be an appropriate alternative in clinical situations that require low-dose inotropic support and diuresis. However, because oliguria in the perioperative period is most commonly a consequence of hypovolemia, these patients may be poorly served by receiving a diuretic such as dopamine. They would be better served by aggressive fluid management and inotropic support aimed at optimizing cardiac output and increasing renal perfusion. Because of the diuretic properties of dopamine, urine output after dopamine administration may reflect only diuresis and not really improved renal perfusion. Finally, dopamine is a neurotransmitter as well as a catecholamine, and administration can produce marked changes in neuroendocrine function, the consequences of which are mostly unknown.
Because of these factors, we believe that there is little role for low-dose dopamine in the perioperative period and in most critical illness, and that the term "renal dose" dopamine should be retired. Unless randomized, controlled clin-
